ArticleCancer immunology, immunotherapy : CII2026
NY-ESO-1 and PD-L1 as biomarkers associated with nivolumab response and outcome in unresectable or recurrent esophageal squamous cell carcinoma: a multicenter biomarker study.
Shigeto Nakai et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.